Therefore, in this study we sought to test the hypothesis that ATM inhibition by AZD1390 (or a structurally related compound, AZD0156) enhances radiation-induced T1IFN responses and sensitizes otherwise resistant pancreatic cancer to immunotherapy, inducing both innate and CD8+ T cell–dependent adaptive immune responses. This evidence concerns the gene CD8A and familial pancreatic carcinoma.